Benefits of statin treatment in cardiac syndrome-X1

Area of Science:

• Cardiology
• Vascular Biology
• Pharmacology

Background:

• Cardiac syndrome-X is characterized by chest pain and normal coronary arteries, potentially due to impaired coronary microvascular endothelial function.
• Endothelial dysfunction leads to inadequate coronary blood flow reserve, contributing to ischemic symptoms.

Purpose of the Study:

• To investigate the effect of statin therapy on endothelial function and exercise-induced ischemia in patients with cardiac syndrome-X.
• To determine if statins, known for endothelial benefits, can improve microvascular function and reduce ischemia in this condition.

Main Methods:

• A randomized, placebo-controlled trial involving 40 patients with cardiac syndrome-X.
• Patients received either pravastatin (40 mg/day) or placebo for 3 months.
• Endothelial function was assessed using brachial artery flow-mediated dilation (FMD) via ultrasound; exercise tests were also performed.

Main Results:

• Pravastatin significantly improved FMD, indicating enhanced endothelial function.
• Statin therapy led to prolonged exercise duration and time to ST-segment depression, with complete resolution of ischemic symptoms in 26% of patients.
• No significant improvements in FMD or exercise parameters were observed in the placebo group.

Conclusions:

• Statin therapy demonstrates significant benefits in improving endothelial function and reducing exercise-induced ischemia in cardiac syndrome-X.
• The findings suggest that improving coronary endothelial function is a key mechanism underlying the therapeutic effects of statins in this patient group.